Exelixis | EXEL - Equity Capital And Reserves


Exelixis reported $2.16B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bayer EUR 25.95B 3.75B Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Exelixis USD 2.16B 619K Dec/2025
Genmab DKK 5.85B 96M Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Xencor USD 635.59M 10.27M Dec/2025